Public Protocol
Platform

Paper

A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial

External resource. Not made or verified by Public Protocol.

Nature Medicine 2025 phase 2a trial of rentosertib in 71 patients over 12 weeks; the authors call for larger, longer trials.

Go to the source

https://doi.org/10.1038/s41591-025-03743-2

Maintainer
Xu and colleagues
Licence, as stated at its source
CC BY-NC-ND
Open or commercial
Not stated by the maker
Maturity
PrototypeOur reading, 16 November 2026
Safety
S3medical
Review
Listed 16 November 2026by Public Protocol editors
Checked
16 November 2026
Next check due
16 May 2027
Steward
Public Protocol editors

Where it sits in the blueprint

Stages

Learn

Elements it supports

Recorded when its maker or a reviewer places it against single elements.

Context

Climate, setting, scale, cost and skill: not stated in this entry. Check the source against your own place and numbers.

Verification

No verification is recorded on Public Platform for this entry. Records are added when someone reads it for accuracy, reviews it with a stated qualification, builds it or measures it.

Record

How it came in

Seed catalogue, 16 November 2026. Listed from Praecise open research. The source was opened and described on the date shown.

Licence

CC BY-NC-ND. Read at https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:40461817%20AND%20SRC:MED&resultType=core&format=json. How licences are recorded